- Home
- SGU vs ARCT Comparison
SGU vs ARCT Comparison
Compare SGU & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- ARCT
- Stock Information
- Founded
- SGU 1995
- ARCT 2013
- Country
- SGU United States
- ARCT United States
- Employees
- SGU N/A
- ARCT N/A
- Industry
- SGU Other Specialty Stores
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- ARCT Health Care
- Exchange
- SGU Nasdaq
- ARCT Nasdaq
- Market Cap
- SGU 388.5M
- ARCT 320.8M
- IPO Year
- SGU 1995
- ARCT N/A
- Fundamental
- Price
- SGU $11.52
- ARCT $17.32
- Analyst Decision
- SGU
- ARCT Strong Buy
- Analyst Count
- SGU 0
- ARCT 10
- Target Price
- SGU N/A
- ARCT $50.88
- AVG Volume (30 Days)
- SGU 39.5K
- ARCT 548.9K
- Earning Date
- SGU 08-06-2025
- ARCT 11-06-2025
- Dividend Yield
- SGU 6.42%
- ARCT N/A
- EPS Growth
- SGU 33.71
- ARCT N/A
- EPS
- SGU 1.66
- ARCT N/A
- Revenue
- SGU $1,777,057,000.00
- ARCT $122,122,000.00
- Revenue This Year
- SGU N/A
- ARCT N/A
- Revenue Next Year
- SGU N/A
- ARCT $31.09
- P/E Ratio
- SGU $6.94
- ARCT N/A
- Revenue Growth
- SGU N/A
- ARCT N/A
- 52 Week Low
- SGU $10.84
- ARCT $8.04
- 52 Week High
- SGU $13.75
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- SGU 42.55
- ARCT 54.49
- Support Level
- SGU $11.55
- ARCT $17.38
- Resistance Level
- SGU $11.72
- ARCT $18.69
- Average True Range (ATR)
- SGU 0.20
- ARCT 1.00
- MACD
- SGU -0.01
- ARCT -0.11
- Stochastic Oscillator
- SGU 5.13
- ARCT 44.23
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.